NASDAQ:GRAL GRAIL Q3 2026 Earnings Date & Estimates $139.91 +7.36 (+5.55%) Closing price 04:00 PM EasternExtended Trading$141.34 +1.43 (+1.02%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. GRAIL is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from GRAIL in Q3 2026GRAIL is expected to post earnings of -$2.45 per share on revenue of $44.21 million. In the same quarter a year earlier GRAIL reported -$2.46 per share on revenue of $36.19 million. GRAIL last reported on August 5, 2026, posting -$2.56 per share and beating the -$2.66 consensus estimate. GRAIL has beaten the consensus EPS estimate in 6 of its last 7 quarters.Consensus EstimatesConsensus EPS-$2.45Expected Revenue$44.21 millionPrior-Year EPS-$2.46Prior-Year Revenue$36.19 millionExpected Revenue Growth+22.1%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$2.56 (Beat by +$0.10)Last Quarter Revenue$44.69 millionEPS Beat Rate6 of last 7 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report GRAIL Q3 2026 Earnings FAQ When does GRAIL report Q3 2026 earnings? GRAIL (NASDAQ:GRAL) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is GRAIL's Q3 2026 earnings call? GRAIL's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for GRAIL? Analysts expect GRAIL to post earnings of -$2.45 per share for Q3 2026. How much revenue is GRAIL expected to report? The consensus revenue estimate for GRAIL is $44.21 million for Q3 2026. GRAIL Earnings HeadlinesWhat GRAIL (GRAL)'s Canada Test Rollout Means For ShareholdersOctober 24 at 9:03 AM | finance.yahoo.comGRAIL consensus price target increased by 32.57% to MX$1,550.35October 23 at 7:25 AM | msn.comExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.October 26 at 1:00 AM | Porter & Company (Ad)GRAIL to Announce Third Quarter 2026 Financial ResultsOctober 21, 2026 | prnewswire.comGRAIL (NASDAQ: GRAL) CEO sells 20,000 shares in preplanned stock saleOctober 20, 2026 | americanbankingnews.comInsider Selling: GRAIL (NASDAQ:GRAL) CEO Sells $2,737,000.00 in StockOctober 19, 2026 | americanbankingnews.comSee More GRAIL Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like GRAIL? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GRAIL and other key companies, straight to your email. Email Address About GRAILGRAIL (NASDAQ:GRAL) (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample. Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S. Food and Drug Administration. GRAIL continues to conduct clinical and real-world studies to evaluate the test’s performance and potential role in cancer screening. GRAIL was founded in 2016 as a healthcare-focused company launched with support from Illumina and became an independent, publicly traded company in 2024. The company is headquartered in Menlo Park, California, and is led by Chief Executive Officer Bob Ragusa. Its commercial and research activities are primarily focused on the United States.View GRAIL ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Anthropic's IPO Filing Reveals a Massive Opportunity for AI Infrastructure GiantsBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockBuy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big CatalystsComfort Systems Earnings: AI Slowdown or More Growth Ahead?MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline Upcoming Earnings Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Baker Hughes (10/27/2026)ONEOK (10/27/2026)Robinhood Markets (10/27/2026)HSBC (10/27/2026)S&P Global (10/27/2026)Visa (10/27/2026)HCA Healthcare (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
